Literature DB >> 24116915

Novel therapy based on camelid nanobodies.

Juan Diego Unciti-Broceta1, Teresa Del Castillo, Miguel Soriano, Stefan Magez, Jose A Garcia-Salcedo.   

Abstract

Nanobodies (Nbs) are small antibody fragments derived from camelid heavy chain antibodies through recombinant gene technology. Their exceptional physicochemical properties, possibility of humanization and unique antigen recognition properties make them excellent candidates for targeted delivery of biologically active components. Several different therapeutic approaches based on the novel camelid Nbs have been developed to treat a wide range of diseases ranging from immune, bone, blood and neurological disorders; infectious diseases and cancer. This review provides a comprehensive overview of the current state of the use of camelid-derived Nbs as novel therapeutic agents against multiple diseases.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24116915     DOI： 10.4155/tde.13.87

Source DB:  PubMed          Journal:  Ther Deliv        ISSN： 2041-5990


  10 in total

1.  Specific Cell Targeting Therapy Bypasses Drug Resistance Mechanisms in African Trypanosomiasis.

Authors:  Juan D Unciti-Broceta; José L Arias; José Maceira; Miguel Soriano; Matilde Ortiz-González; José Hernández-Quero; Manuel Muñóz-Torres; Harry P de Koning; Stefan Magez; José A Garcia-Salcedo
Journal:  PLoS Pathog       Date:  2015-06-25       Impact factor: 6.823

2.  The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis.

Authors:  Maarten Van Roy; Cedric Ververken; Els Beirnaert; Sven Hoefman; Joost Kolkman; Michel Vierboom; Elia Breedveld; Bert 't Hart; Sofie Poelmans; Lieselot Bontinck; Alex Hemeryck; Sandy Jacobs; Judith Baumeister; Hans Ulrichts
Journal:  Arthritis Res Ther       Date:  2015-05-20       Impact factor: 5.156

3.  Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells.

Authors:  Jinle Tang; Jialu Li; Xuejun Zhu; Yuan Yu; Dan Chen; Lei Yuan; Zhenyang Gu; Xingding Zhang; Lin Qi; Zhishu Gong; Pengjun Jiang; Juhua Yu; Huimin Meng; Gangli An; Huyong Zheng; Lin Yang
Journal:  Oncotarget       Date:  2016-06-07

4.  Improving the biophysical properties of anti-ricin single-domain antibodies.

Authors:  Kendrick B Turner; Jinny L Liu; Dan Zabetakis; Audrey Brozozog Lee; George P Anderson; Ellen R Goldman
Journal:  Biotechnol Rep (Amst)       Date:  2015-01-15

5.  Camelid Single-Domain Antibodies: Historical Perspective and Future Outlook.

Authors:  Mehdi Arbabi-Ghahroudi
Journal:  Front Immunol       Date:  2017-11-20       Impact factor: 7.561

6.  South American Camelids: their values and contributions to people.

Authors:  Bibiana Vilá; Yanina Arzamendia
Journal:  Sustain Sci       Date:  2020-10-26       Impact factor: 7.196

Review 7.  Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy.

Authors:  Shuyang Sun; Ziqiang Ding; Xiaomei Yang; Xinyue Zhao; Minlong Zhao; Li Gao; Qu Chen; Shenxia Xie; Aiqun Liu; Shihua Yin; Zhiping Xu; Xiaoling Lu
Journal:  Int J Nanomedicine       Date:  2021-03-22

8.  Identification of antiviral peptide inhibitors for receptor binding domain of SARS-CoV-2 omicron and its sub-variants: an in-silico approach.

Authors:  Swati Singh; Hemanth Naick Banavath; Priya Godara; Biswajit Naik; Varshita Srivastava; Dhaneswar Prusty
Journal:  3 Biotech       Date:  2022-08-01       Impact factor: 2.893

9.  Immuno-targeting the multifunctional CD38 using nanobody.

Authors:  Ting Li; Shali Qi; Mandy Unger; Yun Nan Hou; Qi Wen Deng; Jun Liu; Connie M C Lam; Xian Wang Wang; Du Xin; Peng Zhang; Friedrich Koch-Nolte; Quan Hao; Hongmin Zhang; Hon Cheung Lee; Yong Juan Zhao
Journal:  Sci Rep       Date:  2016-06-02       Impact factor: 4.379

10.  In vivo phage display screening for tumor vascular targets in glioblastoma identifies a llama nanobody against dynactin-1-p150Glued.

Authors:  Sanne A M van Lith; Ilse Roodink; Joost J C Verhoeff; Petri I Mäkinen; Jari P Lappalainen; Seppo Ylä-Herttuala; Jos Raats; Erwin van Wijk; Ronald Roepman; Stef J Letteboer; Kiek Verrijp; William P J Leenders
Journal:  Oncotarget       Date:  2016-11-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.